Monopar Therapeutics Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Monopar Therapeutics Inc. (MNPR) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2024-11-08
- Monopar Therapeutics Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- Monopar Therapeutics Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-06-30 was $0.00.
- Monopar Therapeutics Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was $0.00.
- Monopar Therapeutics Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-12-31 was $0.00.
- Monopar Therapeutics Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 3 quarters · filed 2024-11-08 | $0.00 derived: sum of 4 quarters · filed 2024-11-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |